Exelixis's Cabometyx Positive for First-Line Kidney Cancer

Exelixis Inc EXEL announced results from an analysis of the data from the phase II trial CABOSUN The study compared Cabometyx to Pfizer s PFE Sutent in the first line treatment of intermediate or poor risk advanced renal cell carcinoma RCC patients We note that Cabometyx tablets